Goldman Sachs has downgraded Sartorius Stedim to a "neutral" rating, citing a late-2025 share price rally that has diminished near-term upside potential. The investment bank removed its "buy" recommendation after the stock climbed approximately 25% since the end of August 2025. Goldman Sachs analysts believe the sharp price increase now adequately reflects the anticipated recovery in the bioprocessing market, leaving less room for re-rating compared to other European life science companies.

Despite the downgrade for Sartorius Stedim, Goldman Sachs remains positive on the broader bioprocessing sector. The firm noted that organic sales growth across the industry reached about 10% in the third quarter of 2025, with consumables demand remaining robust. Equipment spending, while softer, is stabilizing.

However, the bank sees greater upside elsewhere, maintaining "buy" ratings on competitors Lonza and Merck KGaA, whose share prices haven't risen as sharply. Goldman Sachs set a new target price for Sartorius Stedim implying roughly 10% upside.